Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Open accessPublished version of a preprint
Abstract
Tumor-associated macrophages (TAM) are one of the most abundant cell types in many solid tumors and typically exert protumor effects. This has led to an interest in macrophage-depleting agents for cancer therapy, but approaches developed to date have had limited success in clinical trials. Here, we report the development of a strategy for TAM depletion in mouse solid tumor models using chimeric antigen receptor (CAR) T cells targeting the macrophage marker F4/80 (F4.CAR-T). F4.CAR-T cells effectively killed macrophages in vitro and in vivo without toxicity. When injected into mice bearing orthotopic lung tumors, F4.CAR-T cells infiltrated tumor lesions and delayed tumor growth comparably with PD-1 blockade, and significantly extended mouse survival. Antitumor effects were mediated by F4.CAR-T–produced IFNγ, which promoted upregulation of MHC molecules on cancer cells and tumor-infiltrating myeloid cells. Notably, F4.CAR-T promoted expansion of endogenous CD8 T cells specific for tumor-associated antigen and led to immune editing of highly antigenic tumor cell clones. Antitumor impact was also observed in mouse models of ovarian and pancreatic cancer. These studies provide proof of principle to support CAR T-cell targeting of TAMs as a means to enhance antitumor immunity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Macrophages have a major advantage over other immune cells for adoptive cell therapy: propensity to migrate and infiltrate into tumors.
“Compared with other immune cells, one major advantage of using macrophages for ACT is the propensity in migration and infiltration into tumors [133].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [133]
The Introduction says tumor-associated macrophages are abundant in solid tumors, and the Results report recruitment of monocyte-derived macrophages to tumor-bearing lungs. These passages support macrophage accumulation in tumors, but do not establish that adoptively transferred macrophages migrate or infiltrate better than other immune cells. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · see citing works
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,065 · see citing works
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,542 · see citing works
SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells
Sachs, P., Ding, D., Bergmaier, P., Lamp, B., Schlagheck, C., Finkernagel, F., Nist, A., Stiewe, T., & Mermoud, J. E. (2019) · Nature Communications · doi:10.1038/s41467-019-09078-0 · Cited by 2,388 · see citing works
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,355 · see citing works
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238 · see citing works
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150 · see citing works
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,057 · see citing works
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works
F4/80, a monoclonal antibody directed specifically against the mouse macrophage
Austyn, J. M., & Gordon, S. (1981) · European Journal of Immunology · doi:10.1002/eji.1830111013 · Cited by 1,580 · see citing works
Žilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H. D., Krishnan, I., Maroni, G., Meyerovitz, C. V., Kerwin, C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.009 · Cited by 1,483 · see citing works
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,477 · see citing works
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-A. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C. D., Levine, J. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.014 · Cited by 1,209 · see citing works
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077 · see citing works
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,029 · see citing works
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 862 · see citing works
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843 · see citing works
Cutting Edge: TREM-2 Attenuates Macrophage Activation
Turnbull, I. R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3520 · Cited by 688 · see citing works
Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
Mulder, K., Patel, A. A., Kong, W. T., Piot, C., Halitzki, E., Dunsmore, G., Khalilnezhad, S., Irac, S. E., Dubuisson, A., Chevrier, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.007 · Cited by 678 · see citing works
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
Molgora, M., Esaulova, E., Vermi, W., Hou, J., Chen, Y., Luo, J., Brioschi, S., Bugatti, M., Omodei, A. S., Ricci, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.013 · Cited by 656 · see citing works
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 644 · see citing works
Zeisberger, S. M., Odermatt, B., Marty, C., Zehnder-Fjällman, A. H. M., Ballmer‐Hofer, K., & Schwendener, R. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603240 · Cited by 622 · see citing works
Overlap Extension PCR Cloning: A Simple and Reliable Way to Create Recombinant Plasmids
Bryksin, A. V., & Matsumura, I. (2010) · BioTechniques · doi:10.2144/000113418 · Cited by 599 · see citing works
Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells
Casanova-Acebes, M., Dalla, E., Leader, A. M., Bérichel, J. L., Nikolić, J., Morales, B. M., Brown, M. K., Chang, C., Troncoso, L., Chen, S. T., et al. (2021) · Nature · doi:10.1038/s41586-021-03651-8 · Cited by 599 · see citing works
Self-citationTuning the Antigen Density Requirement for CAR T-cell Activity
Majzner, R. G., Rietberg, S. P., Sotillo, E., Dong, R., Vachharajani, V. T., Labanieh, L., Myklebust, J. H., Kadapakkam, M., Weber, E. W., Tousley, A. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0945 · Cited by 578 · see citing works
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 526 · see citing works
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512 · see citing works
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466 · see citing works
Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Ma, L., Dichwalkar, T., Chang, J. Y. H., Cossette, B. J., Garafola, D., Zhang, A. Q., Fichter, M., Wang, C., Liang, S., Silva, M., et al. (2019) · Science · doi:10.1126/science.aav8692 · Cited by 439 · see citing works
Interferon-γ Induces Different Subunit Organizations and Functional Diversity of Proteasomes1
Aki, M., Shimbara, N., Takashina, M., Akiyama, K., Kagawa, S., Tamura, T., Tanahashi, N., Yoshimura, T., Tanaka, K., & Ichihara, A. (1994) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a124327 · Cited by 399 · see citing works
Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 392 · see citing works
Targeting TREM2 on tumor-associated macrophages enhances immunotherapy
Binnewies, M., Pollack, J. L., Rudolph, J., Dash, S., Abushawish, M., Lee, T., Jahchan, N. S., Canaday, P., Lu, E., Norng, M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109844 · Cited by 365 · see citing works
Leader, A. M., Grout, J. A., Maier, B. B., Nabet, B. Y., Park, M. D., Tabachnikova, A., Chang, C., Walker, L. A., Lansky, A., Bérichel, J. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.009 · Cited by 356 · see citing works
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
Larson, R. C., Kann, M. C., Bailey, S. R., Haradhvala, N. J., Llopis, P. D. L. M. M., Bouffard, A. A., Scarfò, I., Leick, M. B., Grauwet, K., Berger, T. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04585-5 · Cited by 350 · see citing works
Rodríguez-García, A., Lynn, R. C., Poussin, M., Eiva, M. A., Shaw, L. C., O’Connor, R. S., Minutolo, N. G., Casado‐Medrano, V., López, G., Matsuyama, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20893-2 · Cited by 349 · see citing works
Liang, Y., Wang, M., Chien, C., Yarmishyn, A. A., Yang, Y.-P., Lai, W.-Y., Luo, Y., Lin, Y.-T., Chen, Y.-J., Chang, P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01022 · Cited by 339 · see citing works
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., Brentjens, R. J., Sauter, C. S., Shah, N. N., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00607-3 · Cited by 335 · see citing works
Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer
Etzerodt, A., Moulin, M., Doktor, T. K., Delfini, M., Mossadegh‐Keller, N., Bajénoff, M., Sieweke, M. H., Moestrup, S. K., Auphan‐Anezin, N., & Lawrence, T. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191869 · Cited by 320 · see citing works
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Rodríguez-García, A., Palazón, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 317 · see citing works
Oekelen, O. V., Aleman, A., Upadhyaya, B., Schnakenberg, S., Madduri, D., Gavane, S. C., Teruya‐Feldstein, J., Crary, J. F., Fowkes, M. E., Stacy, C. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01564-7 · Cited by 284 · see citing works
Spatial CRISPR genomics identifies regulators of the tumor microenvironment
Dhainaut, M., Rose, S. A., Aktürk, G., Wroblewska, A., Nielsen, S. R., Park, E. S., Buckup, M., Roudko, V., Pia, L., Sweeney, R. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.015 · Cited by 280 · see citing works
Self-citationCAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 270 · see citing works
Parihar, R., Rivas, C. H., Huynh, M., Omer, B. A., Lapteva, N., Metelitsa, L. S., Gottschalk, S. M., & Rooney, C. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0572 · Cited by 254 · see citing works
DuPage, M. J. P., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R. T., Schmidt, L., Crowley, D. G., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244 · see citing works
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A. X. W., Chan‐Seng‐Yue, M., Wilson, G. W., Grant, R. C., Merico, D., Lungu, I. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.010 · Cited by 231 · see citing works
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 201 · see citing works
Ruella, M., Klichinsky, M., Kenderian, S. S., Shestova, O. E., Ziober, A. F., Kraft, D. O., Feldman, M. D., Wasik, M. A., June, C. H., & Gill, S. I. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0850 · Cited by 194 · see citing works
Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061338 · Cited by 186 · see citing works
IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Alizadeh, D., Wong, R. A., Gholamin, S., Maker, M. S., Aftabizadeh, M., Yang, X., Pecoraro, J. R., Jeppson, J. D., Wang, D., Aguilar, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1661 · Cited by 174 · see citing works
Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens
Wroblewska, A., Dhainaut, M., Ben-Zvi, B., Rose, S. A., Park, E. S., Amir, E.-A. D., Bektesevic, A., Baccarini, A., Merad, M., Rahman, A. H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.022 · Cited by 168 · see citing works
Self-citationChoi, H., Sheng, J., Gao, D., Li, F., Durrans, A., Ryu, S., Lee, S. B., Narula, N., Rafii, S., Elemento, O., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.040 · Cited by 164 · see citing works
Jutila, M. A., Kroese, G. M., Jutila, K. L., Stall, A. M., Fiering, S., Herzenberg, L. A., Berg, E. L., & Butcher, E. C. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181125 · Cited by 151 · see citing works
F4/80 and the related adhesion‐GPCRs
Gordon, S., Hamann, J., Lin, H., & Stacey, M. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141715 · Cited by 151 · see citing works
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Brandt, L. J. B., Barnkob, M. B., Michaels, Y. S., Heiselberg, J., & Barington, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00326 · Cited by 103 · see citing works
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Ishii, K., Pouzolles, M., Chien, C. D., Erwin-Cohen, R. A., Kohler, M. E., Qin, H., Lei, H., Kuhn, S. A., Ombrello, A. K., Dulau‐Florea, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130059 · Cited by 75 · see citing works
Identification of the murine firefly luciferase-specific CD8 T-cell epitopes
Limberis, M. P., Bell, C. L., & Wilson, J. M. (2009) · Gene Therapy · doi:10.1038/gt.2008.177 · Cited by 74 · see citing works
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival
Markowitz, G. J., Havel, L. S., Crowley, M. J. P., Ban, Y., Lee, S. B., Thalappillil, J. S., Narula, N., Bhinder, B., Elemento, O., Wong, S. T. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96836 · Cited by 58 · see citing works
Park, J. A., Wang, L., & Cheung, N. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01156-5 · Cited by 50 · see citing works
Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer
Vonderheide, R. H., & Bear, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605619 · Cited by 48 · see citing works
Anderson, K. G., Voillet, V., Bates, B. M., Chiu, E. Y., Burnett, M. G., Garcia, N. M., Oda, S. K., Morse, C. B., Stromnes, I. M., Drescher, C. W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0258 · Cited by 39 · see citing works
Hartl, C., Bertschi, A., Bou-Puerto, R., Andresen, C., Cheney, E. M., Mittendorf, E. A., Guerriero, J. L., & Goldberg, M. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0654-5 · Cited by 35 · see citing works
A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
Fitzgerald, B., Connolly, K. A., Cui, C., Fagerberg, E., Mariuzza, D. L., Hornick, N. I., Foster, G. G., William, I., Cheung, J. F., & Joshi, N. S. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100080 · Cited by 32 · see citing works
Gomez‐Roca, C., Cassier, P. A., Italiano, A., Cannarile, M. A., Ries, C. H., Brillouet, A., Mueller, C., Jegg, A.-M., Meneses‐Lorente, G., Baehner, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3005 · Cited by 32 · see citing works
Huang, L., Bommireddy, R., Muñoz, L. E., Guin, R. N., Wei, C., Ruggieri, A. N., Menon, A. P., Li, X., Shanmugam, M., Owonikoko, T. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254125 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Makni‐Maalej, K., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M. A., Maccalli, C., Cherif, H., Shahab Uddin, M. S., Steinhoff, M. S., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 638 · see citing works
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270 · see citing works
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223 · see citing works
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 157 · see citing works
Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476904 · Cited by 76 · see citing works
Targeting macrophages: a novel treatment strategy in solid tumors
Liu, M., Liu, L., Song, Y.-P., Li, W., & Xu, L. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03813-w · Cited by 65 · see citing works
Advances in targeting tumor microenvironment for immunotherapy
Wang, L., Zhang, L., Zhang, Z., Wu, P., Zhang, Y., & Chen, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1472772 · Cited by 72 · see citing works
Luo, W., Wen, T., & Qu, X. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02935-3 · Cited by 68 · see citing works
Shao, S., Miao, H., & Ma, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295684 · Cited by 66 · see citing works
Prospects and challenges of CAR-T cell therapy combined with ICIs
Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 61 · see citing works
Du, G., Dou, C., Sun, P., Wang, S., Liu, J., & Ma, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431211 · Cited by 64 · see citing works
Wen, Z., Sun, H., Zhang, Z., Zheng, Y., Zheng, S., Bin, J., Liao, Y., Shi, M., Zhou, R., & Liao, W. (2023) · 癌症：英文版 · doi:10.1002/cac2.12420 · Cited by 58 · see citing works
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
Lamplugh, Z. L., Wellhausen, N., June, C. H., & Fan, Y. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01229-3 · Cited by 71 · see citing works
Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy
Li, C., Yu, X., Han, X., Chen, L., Wang, Z., Shao, S., Shao, F., Wang, H., Ma, S., & Liu, J. (2024) · iScience · doi:10.1016/j.isci.2024.110750 · Cited by 58 · see citing works
Timperi, E., Croizer, H., Khantakova, D., Rana, M., Molgora, M., Guerriero, J. L., Mechta-Grigoriou, F., & Romano, E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1690 · Cited by 49 · see citing works
Macrophages: Targets for next-generation cancer immunotherapy
Sun, X., Park, M. D., Mérad, M., & Brown, B. D. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.020 · Cited by 46 · see citing works
Self-citationGAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
Fan, J., Ye, Y., Yan, L., Yuan, Y., Sun, B., Yang, D., Liu, N., Guo, J., Zhang, J., & Zhao, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01467-9 · Cited by 40 · see citing works
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives
Montoya, M., Gallus, M., Phyu, S. M., Haegelin, J., de Groot, J., & Okada, H. (2024) · Cells · doi:10.3390/cells13090726 · Cited by 40 · see citing works
Su, P., Li, O., Ke, K., Jiang, Z., Wu, J., Wang, Y., Mou, Y., & Jin, W. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5648 · Cited by 37 · see citing works
Macrophages as a Potential Immunotherapeutic Target in Solid Cancers
Mishra, A., Banday, S., Bharadwaj, R., Ali, A., Rashid, R., Kulshreshtha, A., & Malonia, S. K. (2022) · Vaccines · doi:10.3390/vaccines11010055 · Cited by 37 · see citing works
Han, J., Dong, L., Wu, M., & Ma, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160340 · Cited by 35 · see citing works
Tumour-associated macrophages: versatile players in the tumour microenvironment
Ji, Z. Z., Chan, M. K., Chan, A. S. W., Leung, K. T., Jiang, X., To, K., Wu, Y., & Tang, P. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1261749 · Cited by 32 · see citing works
A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors
Liu, H., Noguera-Ortega, E., Dong, X., Lee, W. D., Chang, J., Aday, S., Li, Y., Shin, Y., Shi, X., Liousia, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02845-z · Cited by 30 · see citing works
Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy
Liu, L., Chen, G., Gong, S., Huang, R., & Fan, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274547 · Cited by 31 · see citing works
Mateus-Tique, J., Lakshmi, A., Singh, B., Iyer, R., Sánchez-Paulete, A. R., Falcomatà, C., Lin, M. J., Pantsulaia, G., Tepper, A., Nguyen, T., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.12.021 · Cited by 30 · see citing works
Self-citationLuo, W., Li, C., Wu, J., Tang, L., Wang, X., Zhang, Y., Wu, Z., Huang, Z., Xu, J., Kang, Y. J., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.03.005 · Cited by 30 · see citing works
Nanomaterials Boost CAR‐T Therapy for Solid Tumors
Long, J., Wang, Y., Jiang, X., Ge, J., Chen, M., Zheng, B., Wang, R., Wang, M., Xu, M., Qi, K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304615 · Cited by 28 · see citing works
An update on the clinical trial research of immunotherapy for glioblastoma
Zhou, Y., Shi, F., Zhu, J., & Yuan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582296 · Cited by 26 · see citing works
The current socioeconomic and regulatory landscape of immune effector cell therapies
Sainatham, C., Yadav, D., Babu, A. D., Tallapalli, J. R., Kanagala, S. G., Filippov, E., Murillo-Chavez, F., Ahmed, N., & Lutfi, F. U. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1462307 · Cited by 28 · see citing works
The impact of the tumor microenvironment on macrophages
Xiao, M., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1572764 · Cited by 27 · see citing works
Barriers and solutions for CAR-T therapy in solid tumors
Tu, Z., Chen, Y., Zhang, Z., Meng, W., & Li, L. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00931-7 · Cited by 26 · see citing works
Understanding the complexity of tumor-associated macrophages: Druggable and therapeutic insights
Li, A.-Q., Huang, F., Talaiti, S., Yang, X. Y., Bi, H., & Fang, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.021 · Cited by 25 · see citing works
Li, X., Li, W., Xu, L., & Song, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002818 · Cited by 26 · see citing works
Yin, B., Ding, J., Liu, J., Hu, H., Zhu, Y., Yang, M., Zhou, H., Baoyou, H., Huang, T., Li, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202504436 · Cited by 24 · see citing works
The landscape of CAR-engineered innate immune cells for cancer immunotherapy
Tsahouridis, O., Xu, M., Song, F., Savoldo, B., & Dotti, G. (2025) · Nature Cancer · doi:10.1038/s43018-025-01015-z · Cited by 23 · see citing works
Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances
Brancewicz, J., & Kucharzewska, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679271 · Cited by 23 · see citing works
Yagel, G., Rimini, D., von Locquenghien, M., Avellino, R., Barboy, O., Chalan, P., Granot, G., Xie, K., Shlomi-Loubaton, S., Sheban, F., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.11.009 · Cited by 24 · see citing works
Wang, L., Yang, Z., Guo, F., Chen, Y., Wei, J., Dai, X., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227797 · Cited by 21 · see citing works
Cheng, S., Wang, H., Kang, X., & Zhang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020251 · Cited by 19 · see citing works
Updates in Immunotherapy for Pancreatic Cancer
Chick, R. C., & Pawlik, T. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216419 · Cited by 16 · see citing works
Small-molecule control of CAR T cells
Adams, E. L., McGovern, A. C., So, V., Srinivasan, S., Deiters, A., & Lohmueller, J. J. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00768-6 · Cited by 17 · see citing works
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives
Maher, J. F. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s341179 · Cited by 16 · see citing works
Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis
de león, J. S. A. D., Aguilar, I., & Barb, A. W. (2023) · Glycobiology · doi:10.1093/glycob/cwad078 · Cited by 16 · see citing works
Spiga, M., Martini, E., Maffia, M. C., Ciceri, F., Ruggiero, E., Potenza, A., & Bonini, C. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01011-y · Cited by 15 · see citing works
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 18 · see citing works
Ashrafizadeh, M., Aref, A. R., Sethi, G., Ertaş, Y. N., & Wang, L. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109647 · Cited by 13 · see citing works
Marsico, G., Sudarshan, G. C., & Siciliano, V. (2025) · Small · doi:10.1002/smll.202506429 · Cited by 11 · see citing works
PFC@O2 Targets HIF-1α to Reverse the Immunosuppressive TME in OSCC
Lan, Z., Zou, K., Cui, H., Chen, H. H., Zhao, Y., & Yu, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020560 · Cited by 11 · see citing works
Wu, L., Xia, W., Hua, Y., Fan, K., Lu, Y., Wang, M., Jin, Y., Zhang, W., & Pan, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295442 · Cited by 11 · see citing works
CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws
Sabahi, M., Jouzdani, A. F., Sadeghian, Z., Ohadi, M. A. D., Sultan, H., Salehipour, A., Maniakhina, L., Rezaei, N., Adada, B., Mansouri, A., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04876-z · Cited by 11 · see citing works
From silent partners to potential therapeutic targets: macrophages in colorectal cancer
Khizar, H., Ali, K., & Wang, J. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03965-w · Cited by 11 · see citing works
Zhang, K., Mi, Y., Zhang, B., Xue, X., Ding, Y.-N., Ma, J., Yuan, E., Zhao, X., & Zheng, P. (2025) · Oncogene · doi:10.1038/s41388-025-03322-2 · Cited by 10 · see citing works
Oncogenic CMTM6 drives M2a macrophages formation and fuels cervical cancer progression
Yin, B., Chen, C., Baoyou, H., Ding, J., Hu, H., Zhou, H., Zhu, Y., Huang, T., He, X., Lu, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621816 · Cited by 10 · see citing works
Prospects and challenges of CAR-T in the treatment of ovarian cancer
Chen, B., & Liu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112112 · Cited by 10 · see citing works
Optimising CAR T therapy for the treatment of solid tumors
Mobark, N., Hull, C., & Maher, J. F. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2421194 · Cited by 7 · see citing works
Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy
Guo, H., Wei, J., Zhang, Y., Wang, L., Wan, J., Wang, W., Gao, L., Li, J., Sun, T., & Ma, L. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101158 · Cited by 7 · see citing works
Peptide-based CAR-NK cells: A novel strategy for the treatment of solid tumors
Wang, Q., Yuan, X., Liu, C., Huang, Y., Li, L., & Zhu, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116741 · Cited by 7 · see citing works
Zhang, C., Wang, H., Li, X., Jiang, Y., Sun, G., & Yu, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1526407 · Cited by 7 · see citing works
Mariniello, A., & Migliorini, D. (2026) · iScience · doi:10.1016/j.isci.2025.114609 · Cited by 6 · see citing works
From innate-like to innate: the next wave of off-the-shelf CAR immunotherapies
Feng, Y., Yang, Z., Zhou, Y., LIANG, Y., & Zhao, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691743 · Cited by 6 · see citing works
Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy
Sioud, M., & Casey, N. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020909 · Cited by 8 · see citing works
Wang, Z., ZHOU, L., & WU, X. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.048564 · Cited by 6 · see citing works
Sustained Macrophage Reprogramming Is Required for CD8+ T cell–Dependent Long-Term Tumor Eradication
Jardim, C., Bica, M., Reis-Sobreiro, M., da Mota, A. T., Lopes, R., Pinto, M. F., Sousa, N. S., Mensurado, S., Boekhoff, H., Scolaro, T., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0797 · Cited by 6 · see citing works
Navarre, S., Ishibashi, M., Nair, A., Reyes-Torres, I., Belabed, M., Halász, L., Park, M. D., Mattiuz, R., Ounadjela, M., Gunset, G., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01167-6 · Cited by 6 · see citing works
Self-citationBai, B., Xie, S., Wang, Y., Wu, F., Chen, Y., Bian, J., & Gao, X. H. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1463061 · Cited by 5 · see citing works
Understanding the Dual Role of Macrophages in Tumor Growth and Therapy: A Mechanistic Review
Summer, M., Riaz, S., Ali, S., Noor, Q., Ashraf, R., & Khan, R. R. M. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402976 · Cited by 6 · see citing works
Wu, H., Huang, X., Xu, H., Yang, H., Liu, Z., Liu, F., Ji, F., & Cao, M. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s515895 · Cited by 5 · see citing works
Cucurbitacin I Reverses Tumor-Associated Macrophage Polarization to Affect Cancer Cell Metastasis
Gong, X., Liu, Y., Liang, K., Chen, Z., Ding, K., Qiu, L., Wei, J., & Du, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115920 · Cited by 5 · see citing works
Advancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology
Li, Y., Li, X., Yang, K., & Tong, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1402862 · Cited by 5 · see citing works
Toward the clinical development of synthetic immunity to cancer
Garcia, J. M., Burnett, C. E., & Roybal, K. T. (2023) · Immunological Reviews · doi:10.1111/imr.13245 · Cited by 7 · see citing works
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer
Jin, S., Zhang, Y., Zhou, Z., Zhang, Y., Yu, T., Xu, R., Xu, L., Zhang, J., Zhang, L., Yang, S., et al. (2026) · MedComm · doi:10.1002/mco2.70725 · Cited by 4 · see citing works
CSF1-CAR Specifically Targets CSF1R+ Pancreatic Cancer Cells and Tumor-Associated Macrophages
Zhu, Y., Sun, R., Fan, J., Ma, H., & Sun, B. (2025) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000563 · Cited by 4 · see citing works
Zhang, C., Jiang, X., Li, Y., Liu, F., Shen, Q., Lin, H., & Pang, B. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120579 · Cited by 4 · see citing works
Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment
Budagova, T., Efremova, A. S., Maiak, M. A., & Goldshtein, D. V. (2025) · Cells · doi:10.3390/cells14231858 · Cited by 4 · see citing works
Leveraging macrophage plasticity for precision-targeted tumor immunotherapy
Li, S., Wang, X., Li, L., Chen, L., & Sun, Z.-J. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168176 · Cited by 5 · see citing works
Harnessing myeloid cell plasticity for cancer therapy
Sanseviero, E., Barry, S. T., & Gabrilovich, D. I. (2026) · Nature Cancer · doi:10.1038/s43018-026-01159-6 · Cited by 4 · see citing works
Si, C., Li, Y., Wang, Y., Gao, J., & Ma, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167890 · Cited by 3 · see citing works
CSF1R-CAR T cells induce CSF1R signalling and promote cancer cell growthPreprint
Callahan, K. P., Zhang, X., Wang, A. W., Mojumdar, A., Zeng, L., Su, X., & Salomon, A. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.629028 · Cited by 3 · see citing works
Investigating the Oncogenic and Immunological Implications of YTHDF1 in Ovarian Cancer
Yin, B., & Zhou, H. (2025) · Biologics · doi:10.2147/btt.s542488 · Cited by 2 · see citing works
CSF1R-CAR T cells induce CSF1R signaling and can promote target cell proliferation
Callahan, K. P., Zhang, X., Wang, A. W., Mojumdar, A., Zeng, L., Su, X., & Salomon, A. R. (2025) · Science Signaling · doi:10.1126/scisignal.adv4112 · Cited by 2 · see citing works
Lan, F., Song, J., Chen, X., & (9093), Y. Z. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.02.011 · Cited by 3 · see citing works
Li, H., Liu, C., Zhang, B., Zhang, Y., & Liu, Y. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06471-3 · Cited by 2 · see citing works
Therapeutic potentials of adoptive cell therapy in immune-mediated neuropathy
Shang, S., Zhao, C., & Lin, J. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103305 · Cited by 2 · see citing works
Screening Analysis of Predictive Markers for Cytokine Release Syndrome Risk in CAR-T Cell Therapy
Xu, J., Zhao, C., Wei, Z., Xie, W., Cheng, Q., Zhang, M., Han, S., Kang, L., Xu, N., Yu, L., et al. (2024) · Current Bioinformatics · doi:10.2174/0115748936295986240619162816 · Cited by 1 · see citing works
Understanding Cancer Biology and Microenvironment
Saha, A. K., Mahlawat, P., Kumar, M., & Koralkar, N. V. (2025) · Series in bioengineering · doi:10.1007/978-981-95-0457-2_2 · Cited by 1 · see citing works
Kalander, K., Oksa, K., Sorri, S., Monzó, H. J., Leivonen, S., Ojala, P. M., & Leppä, S. (2025) · HemaSphere · doi:10.1002/hem3.70390 · Cited by 1 · see citing works
Kourtesakis, A., Chow, H. N. H., Bailey, E., Horschitz, S., Jabali, A., Will, R. D., Schifflers, C., Suwala, A. K., Rohdjeß, H., Hahn, M., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201134 · Cited by 1 · see citing works
Sielski, E., Noumani, S. A., Bower, E., Cunningham, K., Beidel, G., Luchianova, A., Courreges, M. C., & Benencia, F. (2026) · Biomolecules · doi:10.3390/biom16030413 · Cited by 1 · see citing works
Khorsandi, K., Ghorayeb, L. E., VanNoy, E. L., & Haydar, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1788956 · Cited by 1 · see citing works
Feng, Y., Wang, Y., Li, X., Wang, Y., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810065 · Cited by 1 · see citing works
Ma, X., Lu, J., Zhong, T., Wang, X., Liu, X., Huo, W., & Chen, X. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1863541 · Cited by 1 · see citing works
Karimi‐Googheri, M., Gholipourmalekabadi, M., Madjd, Z., Shabani, Z., Rostami, Z., Arababadi, M. K., & Kiani, J. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10061-2
Chen, Z., Guan, D., Wang, Y., & Gou, Y. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.06.004
Fan, J., Yu, Y., Yan, L., Yuan, Y., Sun, B., Yang, D., Liu, N., Guo, J., Zhang, J., & Zhao, X. (2024) · Figshare · doi:10.6084/m9.figshare.26605402
Fucoidan-coated Layer-by-layer Lipid Nanoparticles for the generation of CAR-MacrophagesPreprint
Gibson, V. P., Tahiri, H., Omri, S., Filippini, A., Saber, J., Braverman, N., Nogueira, M. C. D. B. L., Banquy, X., & Hardy, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.01.735684
Strategic Advances in CAR Therapy for Solid Tumors: Challenges and Prospective Solutions
Kumar, J., Sharma, S., Roy, S., & Joshi, Y. (2026) · Springer eBooks · doi:10.1007/978-981-95-9777-2_14
Niu, Q., Li, M., Zhang, C., Li, Q., Wang, M., & Liu, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1968080
Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells
Kourtesakis, A., Agardy, D. A., Tejido, C., Hai, L., Hoffmann, D. C. F., Mussnig, N., Sinn, R., Fischer, M. (., Schacht, A., Breckwoldt, M. O., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2745295
- Authors
- Sánchez-Paulete, A. R., Mateus-Tique, J., Mollaoglu, G., Nielsen, S. R., Marks, A., Lakshmi, A., Khan, J. A., Wilk, C. M., Pia, L., Baccarini, A., Merad, M., & Brown, B. D.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- 1Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- Tisch Cancer Institute (US)
- Corresponding author
- Brown, Brian D.
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2022-09-12
- Volume
- 10
- Issue
- 11
- Pages
- 1354-1369
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC10704925
- OpenAlex
- W4295309587
- Cited by
- 98
- References
- 66
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 28 · 2023: 18 · 2022: 2
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Immunology Research (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01CA257195, R01CA254104)
- Alliance for Cancer Gene Therapy
- Applebaum Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- tumor-associated macrophages, chimeric antigen receptor T cells, F4/80, macrophage depletion, antitumor immunity, interferon-gamma, CD8+ T cell proliferation, immunoediting, lung cancer, ovarian cancer, pancreatic cancer, solid tumors
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Antigens, Neoplasm, Disease Models, Animal, Macrophages, T-Lymphocytes, Immunotherapy, Adoptive, Disease Progression, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
